VivoSeq
Metabolic & Endocrine

Hyperglycemia

58

Pipeline Programs↗

7

Active Trials↗

20

Companies Involved↗

Hyperglycemia is a moderately active landscape with 58 programs across 20 companies. The most active players are Sun Pharma, REMD Biotherapeutics, Inc., Gynecologic Oncology Group. 33 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

6/100

Mech. Concentration

16/100

Completion Rate

66/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sun Pharma logo

Sun Pharma

1 program

Phase 1R

REMD Biotherapeutics, Inc.

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Roche logo

Roche

2 programs

Phase 2Amgen logo

Amgen

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

61 of 69 classified programs — the dominant modality here.

12%ALL OTHERSPeptide710%Monoclonal antibody11%

Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 100% of 72 pipeline programs.

Analysis

Trial Status

63

clinical trials

Completed33 · 52%
Terminated13 · 21%
Unknown status6 · 10%
Active, not recruiting5 · 8%
Withdrawn4 · 6%
Recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

63 trials

Insulin Therapy for Postreperfusion Hyperglycemia
Recruiting·SSeoul National University Hospital·Phase 4·NCT03152890·20 enrolled
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
Active, not recruiting·HHealthPartners Institute·N/A·NCT06083038·15 enrolled
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Active, not recruiting·WWake Forest University Health Sciences·Phase 2·NCT03505762·80 enrolled
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Active, not recruiting·MMayo Clinic·Phase 4·NCT05264727·30 enrolled
Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia
Active, not recruiting·LLauro Fabián Amador Medina·Phase 2·NCT06748105·38 enrolled
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes: a Randomized Controlled Crossover Trial
Active, not recruiting·LLoma Linda University·Preclinical·NCT06159543·31 enrolled
Evaluation of Boiled Water Extracts of Legumes Seed Coats for Alpha Amylase and Alpha Glucosidase Activity: Formulation of Anti- Diabetic Nutraceuticals
Enrolling by invitation·JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH·Preclinical·NCT07688694·100 enrolled
Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock
Completed·SSrinakharinwirot University·Phase 4·NCT02266264·80 enrolled
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Completed·MMedanta, The Medicity, India·N/A·NCT06187285·220 enrolled
Hyperglycemia in Renal Transplantation
Completed·UUniversity of California, San Francisco·N/A·NCT01643382·60 enrolled
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Completed·—·Phase 4·NCT01810952·37 enrolled
Comparison of 2 Hyperglycemia-correction Scales in Hospitalized Patients
Completed·—·Phase 4·NCT05752929·116 enrolled
NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens
Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 4·NCT02758522·105 enrolled
Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio
Completed·UUniversity of Diyala·N/A·NCT05822674·80 enrolled
Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
Completed·EEndeavor Health·Phase 4·NCT01545700·200 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)